Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway

被引:77
作者
Li, YX
Higashi, Y
Itabe, H
Song, YH
Du, J
Delafontaine, P
机构
[1] Tulane Univ, Med Ctr, Sch Med, Cardiol Sect, New Orleans, LA 70112 USA
[2] Teikyo Univ, Kanagawa, Japan
[3] Univ Texas, Med Branch, Galveston, TX 77550 USA
关键词
vascular smooth muscle cells; atherosclerosis; growth factors; signal transduction; receptors;
D O I
10.1161/01.ATV.0000099788.31333.DB
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - We have shown previously that oxidized LDL decreases insulin-like growth factor-1 (IGF-1) and IGF-1 receptor expression in vascular smooth muscle cells and that IGF-1 and IGF-1 receptor expression are reduced in the deep intima of early atherosclerotic lesions. Because oxidized LDL is potentially important for the depletion of vascular smooth muscle cells contributing to plaque destabilization, we studied the role of IGF-1 in oxidized LDL-induced apoptosis. Methods and Results - We provide evidence that oxidized LDL-induced apoptosis is caused by decreased mitochondrial membrane potential and increased cytochrome C release in human aortic vascular smooth muscle cells. Overexpression of the IGF-1 receptor by using an adenovirus completely abrogated these effects. The antiapoptotic function of the IGF-1 receptor was associated with increased Akt kinase activity and increased expression of phosphorylated Bad. Moreover, a dominant-negative p85 phosphatidylinositol 3-kinase adenovirus blocked the capacity of the IGF-1 receptor to prevent oxidized LDL-induced apoptosis. Conclusions - Our data demonstrate that IGF-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway and suggest that genetic or pharmacological activation of the IGF-1 receptor may be a useful strategy to stabilize atherosclerotic plaques.
引用
收藏
页码:2178 / 2184
页数:7
相关论文
共 58 条
[1]   Oxidized LDL promotes peroxide-mediated mitochondrial dysfunction and cell death in human macrophages - A caspase-3-independent pathway [J].
Asmis, R ;
Begley, JG .
CIRCULATION RESEARCH, 2003, 92 (01) :E20-E29
[2]   FGF-2, NGF and IGF-1, but not BDNF, utilize a nitric oxide pathway to signal neurotrophic and neuroprotective effects against alcohol toxicity in cerebellar granule cell cultures [J].
Bonthius, DJ ;
Karacay, B ;
Dai, D ;
Pantazis, NJ .
DEVELOPMENTAL BRAIN RESEARCH, 2003, 140 (01) :15-28
[3]   Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor [J].
Brunet, A ;
Bonni, A ;
Zigmond, MJ ;
Lin, MZ ;
Juo, P ;
Hu, LS ;
Anderson, MJ ;
Arden, KC ;
Blenis, J ;
Greenberg, ME .
CELL, 1999, 96 (06) :857-868
[4]   Morphological predictors of arterial remodeling in coronary atherosclerosis [J].
Burke, AP ;
Kolodgie, FD ;
Farb, A ;
Weber, D ;
Virmani, R .
CIRCULATION, 2002, 105 (03) :297-303
[5]   The phosphoinositide 3-kinase pathway [J].
Cantley, LC .
SCIENCE, 2002, 296 (5573) :1655-1657
[6]   Regulation of cell death protease caspase-9 by phosphorylation [J].
Cardone, MH ;
Roy, N ;
Stennicke, HR ;
Salvesen, GS ;
Franke, TF ;
Stanbridge, E ;
Frisch, S ;
Reed, JC .
SCIENCE, 1998, 282 (5392) :1318-1321
[7]   Cellular survival: a play in three Akts [J].
Datta, SR ;
Brunet, A ;
Greenberg, ME .
GENES & DEVELOPMENT, 1999, 13 (22) :2905-2927
[8]  
DEL PL, 1997, SCIENCE, V278, P687
[9]   REGULATION OF VASCULAR SMOOTH-MUSCLE CELL INSULIN-LIKE GROWTH-FACTOR-I RECEPTORS BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES - EFFECTS ON CELL-GROWTH AND EVIDENCE THAT SENSE TARGETING AT THE ATG SITE INCREASES RECEPTOR EXPRESSION [J].
DELAFONTAINE, P ;
MENG, XP ;
KU, L ;
DU, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14383-14388
[10]   G-protein coupled and tyrosine kinase receptors: Evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells [J].
Delafontaine, P ;
Anwar, A ;
Lou, H ;
Ku, L .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) :139-145